Compare Adaptive Biotechnologies Corp (ADPT) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while iShares 1 3 Year Treasury Bond ETF trades at $81.88. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SHY | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $83.18 |
52-Week Low | $12.30 | $81.77 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SHY (iShares 1-3 Year Treasury Bond ETF) trades at $81.94 with minimal daily movement (+0.1%). The technical picture shows bearish momentum with moving averages signaling caution, though oscillators remain neutral. Recent institutional activity indicates growing interest, with Barry Investment Advisors increasing their position by 48.1% in Q2 2026. Treasury yield fluctuations and inflation data remain key drivers for this short-term bond ETF.
Outlook remains tied to Federal Reserve policy and inflation trends. The ETF offers stability with regular dividends but faces headwinds from rising yields. Investment opportunity lies in capital preservation during market volatility, though rising rates could pressure short-term bond prices. Key risks include interest rate sensitivity and macroeconomic policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
